drugset / Trial / NCT00306618
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Colloidal Dispersion (NCD) administered in patients with recurrent glioblastoma multiforme (GBM)
Timeline
- Start
- 2006-01
- Primary completion
- 2007-11
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-methoxyestradiol | Small molecule | 100 mg/ml | Oral |